

Samsung Medical Center Sungkyunkwan University School of Medicine

The Safety of Second Generation DES Is it better now?

Hyeon-Cheol Gwon

Cardiac&Vascular Center, Samsung Medical Center

Sunkyunkwan University School of Medicine



Firestorm from WCC 2006



Meta-analysis by pooling published or presented data







3-100 Probability of Survival Free of Myocardial Infarction (%) Probability of Stent Thrombosis (%) Sirolimus stent After 1 year, SES 0.6%, BMS 0.05% 90-Bare-metal stent p=0.02 2-80-Sirolimus stent HR = 0.97[0.81-1.16]P=0.76 70-Bare-metal stent 60-50-0-0-5 0 2 0 2 Years after Randomization Years after Randomization

Death or MI

Stent Thrombus

Kastrati A, N Engl J Med 2007





Pooled analysis of TAXUS I, II, IV, V



Stone GW, JACC CV Int 2011;4:530



Mechanism of Late ST

- Poor endothelial coverage of the stent
 - Non-specific antiproliferative
 - Thick strut thickness
- Localized hypersensitivity to polymer

Thin strut thickness Biocompatible polymer









Second Generation DES

	Promus Element	Xience Prime	Endeavor Resolute	Biomatrix
Company	Boston Sci	Abbott	Metronic	Biosensors
Drug	Everolimus	Everolimus	Zotarolimus	Biolimus A9
Polymer	Fluorinated	Fluorinated	BioLinx	Bioabsorbable
Strut material	PtCr	CoCr	CoNi	316L
Strut thickness	81 um	81 um	91 um	119 um
Stent design	Element	Multilink 8 ²	Driver	S-stent













Samsung Medical Center Sungkyunkwan University School of Medicine

COMPARE Trial 3Y FU N=1,800

SPIRIT II/III Pooled Analysis N=1,302







Samsung Medical Center Sungkyunkwan University School of Medicine

SORT OUT IV Trial **EXCELLENT** Trial N=2,774 N=1,443 2.01 Definite or probable stent thrombosis (%) 2.0 **Definite Stent Thrombosis Probable Stent Thrombosis** Cardiac death ☆ Cardiac death ☆ Δ Myocardial infarction **Target lesion** p=0.24 revascularization Cumulative incidence rate (%) Log-Rank p-value=0.273 Sirolimus-eluting stent 1.0 SES: 0.8% 1.0 Everolimus-eluting stent 0 EES: 0.4% 0.0 3 12 15 18 6 9 0 Months after initial procedure Follow-up (Months) Numbers at Risk

* Definite or probable stent thrombosis

Jensen LO, Circulation 2012, Park KW, J Am Coll Cardiol 2011



12

Lower ST Risk in New DES SCAAR Registry

Samsung Medical Center Sungkyunkwan University School of Medicine

- Bare meta stent (**BMS**, N=64,631)
- Old DES (o-DES, N=19,202): Cypher, Taxus, and Endeavor
- New DES (**n-DES**, N=10,551): Resolute, Xience, Promus Element



Stent thrombosis: an angiographic occlusion of a previously implanted stent with an acute clinical presentation

Sarno G, European Society of Cardiology 2011



Lower ST Risk in New DES **Bern-Rotterdam Cohort Study**

Observation study in all consecutive patients

EES (n=4,212), SES (n=3,819), PES (n=4,308)



Very Late ST (1-4 yrs)

Räber L, European Society of Cardiology 2011



48

Samsung Medical Center Sungkyunkwan University

School of Medicine

Network Meta-analysis

Samsung Medical Center Sungkyunkwan University School of Medicine

Stent Thrombosis Network Meta-Analysis Protocol





Network Meta-analysis

Samsung Medical Center Sungkyunkwan University School of Medicine

▶ N=50,844, from 49 RCTs

		Odds Ratio (95% Cl
1-Year Definite Stent Thrombosis Rates		1
XIENCE vs. BMS	⊢ ●−1	0.23 (0.13-0.41)
XIENCE vs. Taxus	⊢ ●−-1	0.28 (0.16-0.48)
XIENCE vs. Cypher	⊢ ●−-1	0.41 (0.24-0.70)
XIENCE vs. Endeavor Resolute	⊢	0.14 (0.03-0.47)
XIENCE vs. Endeavor	⊢	0.21 (0.10-0.44)
2-Year Definite Stent Thrombosis Rates		
XIENCE vs. BMS	⊢_	0.35 (0.17-0.69)
XIENCE vs. Taxus	⊢_ ●I	0.34 (0.19-0.62)
1		
0.01	0.1	1 10
←		
	Favors XIENCE	Favors Competitor

Palmerini T, Stone G, Lancet 2012;379:1393–402





EXAMINATION Trial (N=1,504, within 48 hours of STEMI) **Definite/Probable Stent Thrombosis**



Sabate M, TCT 2011



Samsung Medical Center Sungkyunkwan University



Samsung Medical Center Sungkyunkwan University School of Medicine

Polymer Reduced Stent Thrombogenicity



Thin BMS (<100um) Thick BMS (>100um)



Network Meta-analysis

Samsung Medical Center Sungkyunkwan University School of Medicine

▶ N=50,844, from 49 RCTs

			Odds Ratio (95% Cl)
1-Year Definite Stent Thrombosis Rates			
XIENCE vs. BMS	⊢ →→		0.23 (0.13-0.41)
XIENCE vs. Taxus	⊢ ●−1		0.28 (0.16-0.48)
XIENCE vs. Cypher	⊢ ●−−1		0.41 (0.24-0.70)
XIENCE vs. Endeavor Resolute	⊢	i	0.14 (0.03-0.47)
XIENCE vs. Endeavor	⊢		0.21 (0.10-0.44)
2-Year Definite Stent Thrombosis Rates			
XIENCE vs. BMS	⊢		0.35 (0.17-0.69)
XIENCE vs. Taxus	⊢ ●i		0.34 (0.19-0.62)
0.01	0.1	1	10
←			
	Favors XIENCE		Favors Competitor

Palmerini T, Stone G, Lancet 2012;379:1393–402



Xience-V showed Lower Definite ST Rates against Endeavor Resolute

Samsung Medical Center Sungkyunkwan University School of Medicine



Von Birgelen C. TCT 2011, Serruys P, NEJM 2010



Endothelial Coverage of Stent Strut Atherosclerotic Rabbit Iliac Model

Samsung Medical Center Sungkyunkwan University School of Medicine

There is less endothelial cell surface coverage in other DESs compared with EES and BMS.



En Face Confocal Analysis of Comparator Stents









Why is EES better than other DESs? Strut Thickness?

Samsung Medical Center Sungkyunkwan University School of Medicine



3.0 mm diameter stents, 500x magnification. Photos taken by and data on file at Abbott Vascular.



Why is EES better than other DESs? Fluorinated Copolymer?

Samsung Medical Center Sungkyunkwan University School of Medicine

Unheparinized Ex-Vivo Shunt Study



Data from Abbott Vascular



Why is EES better than other DESs? Fluorinated Copolymer?

Samsung Medical Center Sungkyunkwan University School of Medicine

Unheparinized Ex-Vivo Shunt Study





Promus Element vs. Xience–V Same drug, polymer, and strut thickness



Samsung Medical Center Sungkyunkwan University School of Medicine

Stent Thrombosis - ARC Definite



Stone GW, ACC 2012

TCT AP 2012

Next Generation DESs How Can They Prove Better Safety?









Samsung Medical Center Sungkyunkwan University School of Medicine

EXCELLENT Trial 1° EP: Target Vessel Failure (TVF)



* DAT = dual antiplatelet therapy

Gwon HC, Circulation 2012



EXCELLENT Trial TVF in Stent Subgroups



Samsung Medical Center Sungkyunkwan University School of Medicine

(Randomized to EES vs. SES in 3:1 fashion)



Sirolimus-Eluting Stent

Gwon HC, Circulation 2012



RESET Trial



Samsung Medical Center Sungkyunkwan University School of Medicine

E-ZES with 3 mo DAPT vs. Other DES with 12 mo DAPT

- ▶ N=2,117
- E-ZES+3-mo DAPT: 93±28 days (median 93 days)
- Standard therapy: 364±31 days (median 363 days)



Summary and Conclusions



- Second generation DESs seem to be safer than first generation DESs.
- Current evidences suggest that EES have the lowest rate of stent thrombosis compared to BMS as well as other DESs, which needs to be confirmed by a larger RCT data.
- EES should be regarded as the standard against which future design improvements are compared.
- I hope future DES development will focus on the shorter duration of DAPT after the procedure.

